Anti-cancer actions of Denosumab

Jameel Iqbal; Li Sun; Jeffrey I. Mechanick; Mone Zaidi

doi:10.1007/s11914-011-0069-9

Anti-cancer actions of Denosumab

Jameel Iqbal, Li Sun, Jeffrey I. Mechanick, Mone Zaidi

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Denosumab works by binding to and inhibiting receptor activator of nuclear factor-κB ligand (RANKL). Through this mechanism, it can inhibit any cause of bone destruction and thus shows great efficacy in high-turnover osteoporosis. The FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months) trial established the effectiveness of denosumab as a therapy for menopausal bone loss, whereas several newer trials have found denosumab to have shown denosumab to be beneficial in preventing skeletal events from bone metastases. This review highlights the potential novel anti-cancer mechanisms of action of denosumab in mammary tumors.

Original language	English
Pages (from-to)	173-176
Number of pages	4
Journal	Current Osteoporosis Reports
Volume	9
Issue number	4
DOIs	https://doi.org/10.1007/s11914-011-0069-9
State	Published - Dec 2011

Keywords

Bone
Cancer
Dendritic cell
Denosumab
Osteoclast
Osteoporosis
RANK ligand
RANKL
Tumor

Access to Document

10.1007/s11914-011-0069-9

Cite this

@article{4f1295700dbb4a138c956f8122810397,

title = "Anti-cancer actions of Denosumab",

abstract = "Denosumab works by binding to and inhibiting receptor activator of nuclear factor-κB ligand (RANKL). Through this mechanism, it can inhibit any cause of bone destruction and thus shows great efficacy in high-turnover osteoporosis. The FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months) trial established the effectiveness of denosumab as a therapy for menopausal bone loss, whereas several newer trials have found denosumab to have shown denosumab to be beneficial in preventing skeletal events from bone metastases. This review highlights the potential novel anti-cancer mechanisms of action of denosumab in mammary tumors.",

keywords = "Bone, Cancer, Dendritic cell, Denosumab, Osteoclast, Osteoporosis, RANK ligand, RANKL, Tumor",

author = "Jameel Iqbal and Li Sun and Mechanick, {Jeffrey I.} and Mone Zaidi",

note = "Funding Information: Acknowledgments M. Zaidi is supported by grants from the US National Institutes of Health. J.I. acknowledges the support of the American Federation for Aging Research.",

year = "2011",

month = dec,

doi = "10.1007/s11914-011-0069-9",

language = "English",

volume = "9",

pages = "173--176",

journal = "Current Osteoporosis Reports",

issn = "1544-1873",

publisher = "Current Science, Inc.",

number = "4",

}

TY - JOUR

T1 - Anti-cancer actions of Denosumab

AU - Iqbal, Jameel

AU - Sun, Li

AU - Mechanick, Jeffrey I.

AU - Zaidi, Mone

N1 - Funding Information: Acknowledgments M. Zaidi is supported by grants from the US National Institutes of Health. J.I. acknowledges the support of the American Federation for Aging Research.

PY - 2011/12

Y1 - 2011/12

N2 - Denosumab works by binding to and inhibiting receptor activator of nuclear factor-κB ligand (RANKL). Through this mechanism, it can inhibit any cause of bone destruction and thus shows great efficacy in high-turnover osteoporosis. The FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months) trial established the effectiveness of denosumab as a therapy for menopausal bone loss, whereas several newer trials have found denosumab to have shown denosumab to be beneficial in preventing skeletal events from bone metastases. This review highlights the potential novel anti-cancer mechanisms of action of denosumab in mammary tumors.

AB - Denosumab works by binding to and inhibiting receptor activator of nuclear factor-κB ligand (RANKL). Through this mechanism, it can inhibit any cause of bone destruction and thus shows great efficacy in high-turnover osteoporosis. The FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months) trial established the effectiveness of denosumab as a therapy for menopausal bone loss, whereas several newer trials have found denosumab to have shown denosumab to be beneficial in preventing skeletal events from bone metastases. This review highlights the potential novel anti-cancer mechanisms of action of denosumab in mammary tumors.

KW - Bone

KW - Cancer

KW - Dendritic cell

KW - Denosumab

KW - Osteoclast

KW - Osteoporosis

KW - RANK ligand

KW - RANKL

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=81255160572&partnerID=8YFLogxK

U2 - 10.1007/s11914-011-0069-9

DO - 10.1007/s11914-011-0069-9

M3 - Article

C2 - 21874289

AN - SCOPUS:81255160572

SN - 1544-1873

VL - 9

SP - 173

EP - 176

JO - Current Osteoporosis Reports

JF - Current Osteoporosis Reports

IS - 4

ER -

Anti-cancer actions of Denosumab

Abstract

Keywords

Access to Document

Fingerprint

Cite this